F-1: Mainz Biomed N.V. Announces Proposed Public Offering of Ordinary and Pre-Funded Units

Mainz Biomed N.V. plans to offer ordinary and pre-funded units, aiming to raise capital for clinical studies, product development, and commercial expansion.

Summary

• Mainz Biomed N.V. is planning a public offering of up to 2,448,980 ordinary units, each including one ordinary share, a Class A warrant, and a Class B warrant.
• The company is also offering up to 2,448,980 pre-funded units, each including a pre-funded warrant, a Class A warrant, and a Class B warrant, as an alternative for purchasers whose beneficial ownership would exceed 4.99%.
• The assumed offering price is $2.45 per ordinary unit, based on the May 9, 2025 closing price of Mainz Biomed's ordinary shares.
• The exercise price for the Class A and Class B warrants is also assumed to be $2.45, with the Class A warrants exercisable for five years and the Class B warrants exercisable for one year or until 30 days after the eAArly Detect 2 study results are disclosed.
• The pre-funded warrants have an exercise price of $0.0001 and are immediately exercisable.
• The offering is on a best-efforts basis, with Maxim Group LLC acting as the placement agent.
• Net proceeds are intended for the eAArly Detect 2 study, development of a next-generation screening product, commercial expansion of ColoAlert, debt repayment, and general corporate purposes.
• The company estimates net proceeds of approximately $5,330,000 after deducting placement agent fees and estimated offering expenses of $670,000.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document outlines a planned capital raise with both positive aspects (funding for key initiatives) and negative aspects (potential dilution, market risks).

Positives

• The offering aims to fund key initiatives like the eAArly Detect 2 study and the development of a next-generation screening product.
• The company has broad discretion in the use of the net proceeds from this offering.
• The company has collaboration agreements with Life Technologies Corporation and Quest Diagnostics.

Negatives

• The offering is on a best-efforts basis, and there is no guarantee that the company will raise the desired amount.
• Investors will experience immediate and substantial dilution as a result of this offering.
• There is no public market for the pre-funded warrants, Class A warrants, or Class B warrants.
• The company does not intend to pay dividends, which limits potential gains for investors.
• The company may lose its foreign private issuer status, leading to increased compliance costs.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the company's ordinary shares may be volatile.
• Investors will experience immediate and substantial dilution as a result of this offering.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• There is no public market for the pre-funded warrants, Class A warrants, or Class B warrants being offered in this offering.
• The company may lose its foreign private issuer status in the future, which could result in significant additional cost and expense.
• Changes to United States tariff and import/export regulations could negatively affect the company's business condition and results of operations.
• Changes in U.S. government policies under the current administration, including reductions in federal research funding and cuts to regulatory review staff at the FDA could adversely affect the company's business.

Future Outlook

The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next generation screening product, the commercial expansion of its ColoAlert product, repayment of debt and for general corporate purposes.

Management Comments

• Our mission is to enhance disease diagnosis by applying cutting-edge genetic diagnostic technologies, enabling earlier and more accurate detection for timely and improved treatment.

Industry Context

The colorectal cancer diagnostics market is anticipated to surpass $30 billion by 2032, presenting a significant opportunity in the molecular diagnostics market.

Comparison to Industry Standards

• The UdeS Biomarkers consist of five gene expression markers shown to be highly effective in detecting colorectal cancer (CRC) lesions, including advanced precancerous lesions, AAs, a type of precancerous polyp often associated with CRC.
• In a UdeS-sponsored study evaluating these biomarkers, results demonstrated sensitivities of 75% for detecting AA and 95% for CRC, with a specificity of 96%.
• The eAArly DETECT study enrolled 254 evaluable subjects across 21 sites in the United States, featuring a design similar to that of ColoFuture.
• In June 2024, the Company presented pivotal data from its largest cohort to date during a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois.
• This data combined results from the ColoFuture and eAArly DETECT studies, along with additional patients collected since the initial study results were reported, underscoring the significance of our innovative screening approach.
• The combined analysis included 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the United States, incorporating previously unexamined and unreported samples.
• This highlighted the exceptional efficacy of Mainz Biomeds multimodal screening test, which integrates the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, supported by an advanced AI and machine learning algorithm.
• This comprehensive approach allows for precise differentiation between colorectal cancer (CRC), AAs, non-advanced adenomas, and samples with no pathological findings.

Legal Proceedings

• Mainz filed a lawsuit against an investment bank in 2024 in the New York State Supreme Court in New York County, asking the court to determine our and the investment banks rights and obligations under the relevant contracts by and between us and the investment bank.
• Shortly after our filing of such lawsuit, the investment bank initiated arbitration proceedings against us with the Financial Industry Regulatory Authority (FINRA).
• Thereafter, we requested the arbitration panel stay its proceeding in light of the existing lawsuit.
• The arbitration panel agreed with us and on September 13, 2024, issued an order formally staying the arbitration proceeding.
• There is not a future court conference scheduled, and we are waiting on the Courts determination of which venue (the Supreme Court or FINRA Dispute Resolution) is proper to hear the dispute.
• We intend to vigorously defend against all claims.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may benefit from the company's continued operations and growth.
• Customers may benefit from improved diagnostic products and services.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Complete the public offering of ordinary and pre-funded units.
• Conduct the eAArly Detect 2 study.
• Develop the next-generation screening product.
• Expand the commercial reach of ColoAlert.
• Repay debt.
• General corporate purposes.

Key Dates

Keywords

public offering, ordinary units, pre-funded units, warrants, Mainz Biomed, capital raise, MYNZ, ColoAlert, eAArly Detect 2, diagnostics